What if we could remove diseases at the cellular level to stop them from growing before they begin?
Specific Biologics, a JLABS @ Toronto company recently selected as one of the first BLUE KNIGHT™ companies, is aiming to do just that.
Join us October 13 to hear from Brent Stead, CEO, of Specific Biologics, who will present on how the company’s gene editing platform technology differs from the well-known CRISPR-Cas9, and could more accurately correct errors at the genetic level in cells inside the body.
This program is part of BLUE KNIGHT™, a collaboration between Johnson & Johnson Innovation – JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA).
Johnson & Johnson Innovation – JLABS is collaborating with the Biomedical Advanced Research and Development Authority (BARDA), a component of the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services to form Blue Knight. This collaboration aims to stimulate innovation and incubation of technologies that improve health security and response through companies focused on public health threats and emerging infectious diseases. Find out more about BARDA and its mission at www.PHE.gov/BARDA.
Brent is co-founder and CEO of Specific Biologics, a discovery stage company developing gene editing technologies for therapeutic use. Prior to Specific Biologics, Brent worked for 7 years in the biotechnology industry in various capacities, most recently in business development for a biologics development and manufacturing organization. He started his career in the life sciences as a Ph.D. graduate of Western University’s biochemistry program and completed his MBA at the Richard Ivey School of Business.
Ashley Cecere, M.S. serves as a Biologist/Project Officer at Biomedical Advanced Research and Development Authority (BARDA) within the US Department of Health and Human Services. Ashley serves as the technical lead at BARDA for the JLABS collaboration. This collaboration is aimed at stimulating innovation and incubation of technology in areas of mutual interests to BARDA and JLABS and that improve our nation’s health security.
As Head of Johnson & Johnson Innovation, JLABS in Canada, Allan is responsible for external engagement, innovation sourcing, company onboarding, portfolio management, operational excellence, educational programming and P&L. He catalyzes and supports the translation of science and technology into valuable solutions for patients and consumers across the pharmaceutical, medical device, consumer and healthtech sectors.
Johnson & Johnson Innovation – JLABS Notice
The views expressed during this event, including during any associated networking and/or individual meetings by anyone other than an employee of Johnson & Johnson Innovation LLC, its parent company or any affiliate companies (herein after referred to as “JJI”) are those of the speakers or experts alone, and such experts or speakers are solely responsible for the information and opinions expressed by them. By hosting this event, the presentations and any associated networking and/or individual meetings, JJI does not endorse the views of the speakers, experts or the attendees, and JJI makes no warranties, express or implied, as to the content, the views, advice or the information
